Simvastatin-induced meralgia paresthetica.

Area of Science:

• Neurology
• Pharmacology

Background:

• 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are widely prescribed for hyperlipidemia.
• Muscular adverse effects are the most common side effects associated with statin therapy.
• Peripheral neuropathy has been reported as a rare adverse effect of statins, with an incidence of approximately 1 in 10,000 patients per year.

Observation:

• Meralgia paresthetica, an entrapment neuropathy affecting the lateral femoral cutaneous nerve, is occasionally diagnosed in primary care.
• This report describes a case of meralgia paresthetica that was potentially aggravated by the use of simvastatin.
• The patient experienced symptom resolution upon discontinuation of simvastatin.

Findings:

• This is the first reported case linking statin use, specifically simvastatin, to the aggravation of meralgia paresthetica.
• The temporal relationship suggests a possible causal or exacerbating role of simvastatin in this patient's condition.
• Cessation of simvastatin led to the improvement of meralgia paresthetica symptoms.

Implications:

• Clinicians should consider statin-induced nerve entrapment, such as meralgia paresthetica, in patients presenting with these symptoms.
• Further investigation may be warranted to elucidate the mechanism by which statins could influence entrapment neuropathies.
• This case highlights the importance of medication review in managing peripheral neuropathies.